BRIEF—Ryaltris picks up Canadian approval

Canada’s Bausch Health and India’s Glenmark Pharmaceuticals have received approval for Ryaltris (olopatadine hydrochloride/mometasone furoate) in Canada.

The firms have been given the green light for marketing the nasal spray, for moderate to severe seasonal allergic rhinitis and associated ocular symptoms.

Glenmark  won approval in Europe in 2021, and in the USA in early 2022, where the product is marketed under license by Hikma Pharmaceuticals.

Bausch Health senior vice president Cees Heiman said: "This Health Canada approval will allow Bausch Health to soon make Ryaltris available to Canadians, providing an innovative therapy option for seasonal allergic rhinitis.”